HC Wainwright reaffirmed their buy rating on shares of Cardiol Therapeutics (NASDAQ:CRDL - Free Report) in a report released on Wednesday morning,Benzinga reports. They currently have a $9.00 price target on the stock.
Cardiol Therapeutics Stock Up 5.1 %
Shares of NASDAQ:CRDL traded up $0.07 during trading on Wednesday, reaching $1.44. 114,000 shares of the company traded hands, compared to its average volume of 416,907. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The firm has a market cap of $117.64 million, a P/E ratio of -3.64 and a beta of 0.83. Cardiol Therapeutics has a 1-year low of $0.79 and a 1-year high of $3.12. The firm has a fifty day simple moving average of $1.72 and a 200 day simple moving average of $1.98.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in Cardiol Therapeutics in the 3rd quarter valued at $29,000. Townsquare Capital LLC bought a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth about $27,000. Wealth Enhancement Advisory Services LLC bought a new stake in Cardiol Therapeutics in the 3rd quarter valued at $27,000. Foundations Investment Advisors LLC grew its stake in shares of Cardiol Therapeutics by 237.4% in the third quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company's stock valued at $321,000 after acquiring an additional 113,950 shares in the last quarter. Finally, Lion Street Advisors LLC grew its position in shares of Cardiol Therapeutics by 7.9% during the 3rd quarter. Lion Street Advisors LLC now owns 273,281 shares of the company's stock worth $544,000 after purchasing an additional 20,000 shares in the last quarter. 12.49% of the stock is currently owned by institutional investors.
Cardiol Therapeutics Company Profile
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Read More
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
